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I think ofa clinical investigator as one trying to ride two horses -
attempting to be an investigator and a clinician at one and the
same time. Whereas such an equestrian manoeuver is usually con-
sidered a badpolicy, in this case.. .experience has shown that it






The fatty alcohol cholesterol, wrapped in molecules of lipopro-
teins, travels through the bloodstream to the body's cells to re-
pair membranes and make steroid hormones. Other lipoproteins
- proteins with fats, or lipids, attached to them - remove cho-
lesterol from tissues and take it back to the liver where it is proc-
essed for disposal. When cholesterol metabolism is functioning
normally, the liver makes most of the cholesterol the body uses.
The cholesterol absorbed from food restrains the liver's produc-
tion ofcholesterol, keeping the supply in balance with the body's
needs. But as no one today needs reminding, sometimes choles-
terol metabolism doesn't function normally. In the process of
atherosclerosis, for example, cholesterol builds up on the walls
of arteries and blocks the life-sustaining flow of blood to the
heart and other organs.
In the 1940s, when Edward H. Ahrens, Jr. was drawn un-
expectedly into the "murky business of lipids," there was cir-
cumstantial evidence that dietary fats playa role in
atherosclerosis and heart disease bur almost no means for inves-
tigating this scientifically. In a few years, the picture had
changed dramatically. New technologies, developed or refined
by Dr. Ahrens and others, made it possible to sort our the con-
fusion offatty compounds in the body, and in the 1950s his lab-
oratory provided definitive confirmation that the kind of fats we
eat can alter the level of cholesterol in our blood. The terms "sat-
urated" and "unsaturated" entered the popular vocabulary and,




Dr. Ahrens and patient in the
Rockefeller University Hospital.
as he later wrote, "the sleepy old field of lipid research took off
for the moon." Today he is a spirited parcicipant in the ongoing
debate over dietary and other strategies for coping with choles-
terol problems.
Dr. Ahrens is Frederick Henry Leonhardt Professor of The
Rockefeller University and a senior physician in the University's
research hospital whete patients with disorders that science still
cannot fully explain, prevent, or cure, like atherosclerosis, par-
ticipate in experiments and receive free treatment and counsel.
• Trained as a pediatrician, he first came to Rockefeller to study
liver diseases. His interest was endocrinology, and the liver is a
major processing center for hormones. But the first patient as-
signed to him on his arrival was suffering from a disease in
which cholesterol metabolism had gone badly awry. His initia-
tion into "cholesterol-watching," as he calls it, produced the first
detailed description of the disease, which he named primary bil-
iary cirrhosis, and led him to decide that lipids weren't as
"charmless" as he had thought.
The major difficulty at the time was in purifying fats: isolat-
ing them from one another and from other body compounds.
Since some of the best work in separation technology was being
done at Rockefeller, Dr. Ahrens spent two years with Lyman
Craig, inventor of a method called COuntercurrent distribution,
which separates mixtures into their component parts by differ-
ences in their partitioning between two solvents. Down the hall
from Craig's laborarory, Stanford Moore and William Stein,
later to receive the Nobel Prize, were purifying amino acids by
chromatography, a technique that takes advantage of the fact
that various closely related compounds adhere differently to ma-
terials they pass through. Dr. Ahrens learned both procedures
and was the first scientist in the country to adapt gas-liquid
chromatography to fatty compounds, an innovation the Ameri-
can Hearc Association credited with helping to "revolutionize
the field of lipid chemistry."
"FEED THEM LIKE BABIES"
In 1952 he turned to the problem of atherosclerosis. That the
quality of dietary fats rather than simply their quantity might
be a precipitating factor had been suggested by Laurance W
Kinsell, an endocrinologist trained by Fuller Albright at Har-
vard Medical School, the same teacher who had inspired Dr. Ah-
rens. "Kinsell had observed that animal fats raised cholesterol
levels in the blood while vegetable fats lowered them," says Dr.
Ahrens, "but since his experiment had been designed to study
hormones, with cholesterol thrown in as an afterchought, not roo
many people took him seriously. I decided to design an experi-
ment specifically to test this point.
"We had an awful time at first. It was boring as the devil for
the patients, who had to eat the same diet every day for weeks.
It was hard on the dietitians, and we didn't have precise enough
control of the dietary mix. I was telling my troubles to one of
our elder pediatric statesmen one day, Dr. Emmett Holt, whose
father was a member of the first board of The Rockefeller. Holt
just looked at me, disgusted. 'I thought you were a pediatrician,'
he said. 'Feed them like babies. Feed them formula.' Well, of
course, that was the solution and the birch of the formula diets
that are used so widely now in clinical experimentation.
"After we found a basic mixture that could stand up to our
manipulations, we tested about forty fats on several hundred pa-
tients. We not only confirmed that different fats change choles-
terollevels, we found out that the effects depend on the degree
of saturation." (Unsaturated fats, like vegetable and fish oils, are
liquid at body temperature. Saturated fats, like those in meat
and cheese, have much higher'melting points.)
A young cardiologist named Jules Hirsch, one of the first of
many researchers who have come to Rockefeller over the years to
work with "Pete" Ahrens, as he is universally known, was on the
project and also worked on refining chromatography methods.
Dr. Hirsch explains: "Cholesterol occurs in a free state or at-
tached to fatty acids. Other fats in the blood have the same fatty
acids, but in different chemical configurations. With chroma-
tography we were able to start breaking down these mixtures
and follow them individually, which no one had done befote. We
were able to determine how fats are distributed in the body and
analyze what was happening in the gastrointestinal tract as they
were absorbed ...
In planning the experiment, Dr. Ahrens hit on the idea of re-
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Cholesterol is a major component of
cell membranes and steroid hormones,
and that part of it converted to bile
acids plays an essential role in
/at absorption and digestion,
In normal cholesterol metabo-
lism, the daily rate ofsynthesis in
the liver, the principal site of
cholesterol manufacture in the body,
is equal to the difference between
dietary intake and excretion, The
average level ofplasma cholesterol in
the United States is now about
220 milligrams per 100 milli-
liters of blood plasma. An elevated
level ofplasma cholesterol is a
major risk /actor /or atherosclerosis.
Malfunctions ofcholesterol
metabolism can be attacked by
means ofdietary intervention,
drugs, or surgical procedures. All
of these act at various points
along the metabolic pathway to:
modify cholesterol intake (A ),' re-
duce absorption (B),. enhance the
formation of bile acids (C ),'
increase the outflow of tissue choles-
terol (D),. reduce synthesis in the
liver and other ti.rsues (E),' or
physically remove cholesterol from
the blood, as in LDL pheresis
(see page 6).
cruiting overweight people, to whom he promised (and deliv-
ered) weight reduction. He has since confined his studies to
patients whose concern is clearly arterial disease. Dr. Hirsch,
still at Rockefeller, went on to direct one of the country's leading
programs for the study of obesity.
DELVING INTO THE TREASURE HOUSE
By 1960 Dr. Ahrens was ready to tackle the question of the
. mechanisms of cholesterol regulation. "We knew we could con-
trol the intake of cholesterol with formula feeding," he says,
"but to find out how much cholesterol the body was making we
had to compare intake against outflow, the route of disposal
being the feces. It wasn't an easy job. The feces are a jumble of
many materials. Emil Fischer called them the treasure house of
biochemistry. Well, we starred delving into the treasure house
like Midas. We got the gold, but it tOok a long time.





"To complicate matters, we knew the skin has sterols in it,
tOo, and we didn't know if they would affect our calculations.
That worry led us into one of the most trying and bizarre ex-
periments we've ever done. We wrapped a handful of poor souls
in specially made suits, head to tOe, and every day we'd rub
them down, take the clothing to the lab, and measure the fat in
it. The worst parr for us was preparing the suits. Almost all
cloth is made with sizing, which is full offar. Before we could
use the stuff, we had to put it in huge vats of solvent, over and
over again for days, to be sure the sizing was out. It was a great
relief to learn that cholesterol in the skin is made in the skin and
doesn't citculate. We didn't have to do any more laundry."
During this period, researchers elsewhere introduced the
ptactice of feeding patients cholesterol tagged with radioactive
isotopes, which makes it easier to track through the body.
After more than a decade and hundreds ofexperiments on the






technique known as the sterol balance method, which accurately
measures the difference between dietary intake and total daily
excretion: this difference is due to the body's own manufacture
of cholesterol. With sterol balance methods and isotope feeding,
he was able for the first time to measure precisely the dietary in-
take of cholesterol, its absorption from the intestines, conversion
to bile acids, body synthesis rates and its feedback control,
transfer of stored pools of cholesterol in and out of tissues, and
excretion rates. (See diagram, page 3.)
He learned not only how cholesterol metabolism is regulated,
but also how differently it is regulated in different people, a find-
ing he considers his most significant scientific contribution.
This concept underlies all the work in his laboratory now and is
the basis of the skepticism he has expressed about some of the
recent publicity on dietary cholesterol.
"Blood levels of cholesterol are useful indicators of people at
risk," he states, "but the important question to ask about such
a person, once identified, is why the level is elevated; is the body
making or absorbing too much cholesterol or not excreting
enough? Most treatment is aimed simply at lowering blood lipid
levels, which is not necessarily beneficial. Using our sterol bal-
ance methods, we saw, for example, that people on an unsatu-
rated-fat diet usually reduce the pool of plasma cholesterol by
shifting it from the plasma into the bulk tissues - muscle, con-
nective tissue, and adipose tissue; and with various other ma-
nipulations, we showed that the excess cholesterol stored in
tissues can be vastly reduced without significantly altering the
plasma levels.
"Our aim is to develop further means for pinpointing defects
and individualizing treatments in the most appropriate way.
Thus, we'd like to see to what extent we can predictably affect
the atherosclerotic process or even reverse it if possible, which no
one has yet shown can be done."
NEW DIRECTIONS
Sterol balance methods require hospitalization for many weeks
on a formula diet. Donald J. McNamara, a member of Dr. Ah-
rens' group since 1974, is a biochemist whose research into the
chemistry and physiology of cholesterol metabolism has led to
quicker and easier tests. One of the procedures he has introduced
resulted from studies of mevalonic acid that he conducted with
Thomas Parker, another biochemist in this lab.
"Mevalonic acid, or mevalonate, is a precursor stage in cho-
lesterol synthesis," Dr. McNamara explains. "Your body must
make mevalonate before it can make cholesterol. While we were
investigating mevalonate synthesis, Tom and I realized we could
pur it to work clinically. In the method we've designed, we feed
a patient a high-cholesterol diet and take a blood sample. If we
see a change in the level of mevalonate compared to baseline lev-
els, we know that a change in the cholesterol level is the result
of a change in synthesis. The whole thing takes twenty min-
utes. "
Cholesterol metabolism has rarely been studied in children or
in women of child-bearing age because of the potential danger
of using radioactive tracers. Lisa Hudgins, the newest member
of the laboratory, has synthesized a non-radioactive tagged cho-
lesterol; its effectiveness is currently being checked against re-
sults obtained with radioactive isotopes.
"When we're sure it works," she says, "and at this point it
looks good, we want to starr by measuring cholesterol absorp-
tion, which hasn't been measured in normal infants or children.
In today's world, parents have been advised to feed their children
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Thomas Parker, left, and
Donald McNamara with their
apparatus for measuring
concentrations of mevalonic acid
in plasma samples from pa-
tients. Mevalonic acid is a pre-
wrsor stage in the synthesis
of cholesterol.
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play God with people the way you can with laboratory mice or
molecules, but it can also pay big dividends in terms of basic sci-
ence as well as in practical therapeutic terms."
Clinton Brown, who has just completed a clinical fellowship
and, like Dr. Hudgins, plans to continue in research, conducted
an experiment in Dr. Ahrens' laboratory with a technique that
had never been tried before in the treatment of coronary artery
disease. His patient, a man in his mid-fifties, lived for nearly
two years solely on intravenous feeding, what is called total par-
enteral nutrition (TPN). "It takes a lot of motivation to live
without food in the mouth," says Dr. Brown, "and Jack has it.
He's had twO heart attacks and his mother died of heart disease.
He's not a suitable candidate for bypass surgery, and when he
came to us his angina was so bad he couldn't work."
TPN is conventionally used with people who have lost part of
their intestinal tract through injury or surgery. "There is very
little literature on cholesterol metabolism in these patients," Dr.
Ahrens says, "but they don't seem to suffer coronaries. We won-
dered if we could use TPN not just to slow Jack's cholesterol
buildup, but perhaps also to make it regress."
Dr. Brown put his patient on a regimen in which the sub-
stance used to hold together the fat emulsion in the TPN diet
was phospholipid, a lipid with phosphorus attached, which also
travels in the blood with cholesterol. "We think phospholipid
acts as a detergent," says Dr. Brown. "With TPN we were able
to bring Jack's synthesis rate'down to normal. He feels great.
Now we have to find Out whether or not the phospholipid has
pulled stored cholesterol from his arterial tissue."
Last summer an eleven-year-old could be glimpsed at Rocke-
feller dancing around to her Walkman and chasing after the lab-
oratory's volleyball team. Her name is Katenia, and she is among
several children - the youngest is three - under treatment at the
hospital for a rare genetic disorder called familial hypercholes-
terolemia, or FH.
FH represents a catastrophic failure of the cholesterol trans-
port system. The carriers that take cholesterol from the liver to
the cells are called low density lipoproteins (LOL). There are re-
ceptor molecules on cell surfaces that "recognize" LOL, attach to
it, and escort the LOL-cholesterol complex into the cell. In peo-
a low-cholesterol diet, but in fact we don't know to what extent
infants absorb cholesterol, or whether there is a difference in ab-
sorption between normal children and children from families
with histories of heart disease. We want to learn how cholesterol
metabolism changes with age. We want to study a spectrum of
families with different health histories. We want to find out if
functional differences can be identified early in life."
Dr. Hudgins, a pediatrician like Dr. Ahrens, came to Rocke-
feller as a clinical fellow, a program established at the hospital
• in 1976 to provide young physicians with opportunities for
hands-on experience in experimental medicine. Such opportun-
ities have been drastically curtailed throughout the country in
recent years. It's a subject Dr. Ahrens feels strongly about. In a
retrospective article he wrote this past summer for the twenty-
fifth anniversary volume of the Journal of Lipid Research (a pub-
lication he founded and which he edited during its first years),
he recalled that the strongest impression of his own initiation
into the field was "the realization of how rewarding patient-ori-
ented research can be. It's been a tradition at Rockefeller since
its founding, and one of its glories. But I worry," he says, "that,
if the present national trend continues, clinical scientists will
become an extinct breed. That would be a great shame. Clinical




Clinton Brown recently con-
ducted an experiment in which
a patient was fed intravenously
with a diet containing a
substance which may act to draw
cholesterol out of tissues. In
conjunction with the clinical
study, Dr. Brown, shown here in
the Laboratory Animal Research
Center at Rockefeller, administered
the substance to hypercholesterolemic
rabbits whose arteries will be
dissected and compared with a
control group ofanimals.
Lisa Hudgins and a patient-
volunteer con.rult on the sun
deck of the Hospital. Dr.
Hudgins, who is currently
studying cholesterol metabolism
in children, is concerned
with the question ofhow the




pie with FH, the genes that code for the receptor are defective.
LOL-cholesterol doesn't get into the cells, so the liver keeps on
making cholesterol and copiously turning it out into the blood
plasma. Children born with the worst form of the disease, like
Katenia, rarely live past their twenties.
When she first came to Dr. Ahrens, Katenia had the telltale
lumps of cholesterol in her skin and wildly elevated blood cho-
lesterol levels typical of these children, and she wasn't doing
much dancing. After testing, Dr. Ahrens recommended her for
• a portacaval shunt, an operation that redirects the blood from
the intestines around the liver so that the liver makes less cho-
lesterol. In addition, she goes for LOL pheresis every week or
two, a procedure in which her blood is pumped out and the
plasma portion is passed through a column in which antibodies
remove the LOL. LOL pheresis was invented by Willi Stoffel of
the University of Cologne, a former member of Dr. Ahrens' lab-
oratory. Dr. Parker learned the procedure from Professor Stoffel
and now supervises a joint Rockefeller-New York Hospital team
that performs it at New York Hospital.
The lumps in Katenia's skin are gone and her blood choles-
terol level is much lower, if not normal. Her status is moni-
tored every six to twelve months with repeat cardiac and
metabolic studies in the Rockefeller University Hospital.
Whether these interventions will slow the course of her illness
only time will tell.
THE DIET DEBATE
FH represents far less than five percent of coronary artery dis-
ease. What causes the other 95 percent? Smoking, high blood
pressure, and high blood fats can lead to lesions on artery walls
that are rich in cholestetol. Recent discoveries about the normal
roles of lipoproteins have generated important new understand-
ing of the genetics of their formation, as well as the factors, in-
cluding diet and exercise, that affect their levels in the blood:
too high a level of LOL is believed to contribute to atheroscle-
rosis, while HOL (high density lipoproteins, the ones that
transport cholesterol out of tissues), are considered beneficial.
Last January, a report was released showing that in a ten-year
trial of a large number of men with high blood cholesterol lev-
e1s, the rate of heart attacks was reduced when the lipid-low-
ering drug cholestyramine was administered. The report has
been cited as definitive proof of the efficacy of lowering blood
levels by any means, including diet. But Dr. Ahrens feels that
it is "not scientifically sound to extrapolate drug results to ad-
vice on diet for people in whom synthesis-absorption feedback
regulation works efficiently." For instance, in a recent test of
fifty-one patients who were healthy except for high blood cho-
lesterol levels, Dr. McNamara found that seventy-five percent
showed reduction of cholesterol synthesis on higher cholesterol
intake - evidence of good feedback control - and only fifteen
percent showed an increase in plasma cholesterol levels. Dr.
McNamara points out that low-fat diets lower both LOL and
HOL levels, and states that "maintaining a constant ratio of
LOL to HOL may in actuality confer no real benefit."
Dr. Ahrens worries that drastic changes in fat consumption,
both in quality and quantity, which have been observed to
change cell-membrane structure, may have undesirable effects
on an individual's immunologic responsiveness and susceptibil-
ity to other diseases. He would prefer to see people follow com-
mon-sense measures against smoking, obesity, and stress (which
raises LOL levels) while maintaining a balanced diet. He urges
that the health community direct its attention "to the twenty
percent or so of the population at the top end of the blood cho-
lesterollevel scale who need vigorous, individualized testing and
treatment. It's not a popular 'theme song these days," he says,
laughing, "but more and more experts are learning the tune."
While the great debate continues, Dr. Ahrens finds comfort
in planting trees in an arboretum that he and his wife started
seven years ago in the Catskills. Their more than three hundred
species are, he reports, "living happily on a dietary regimen that
seems to give rise to no signs of atherosclerosis."
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